journal article·2025-09-10Open access

Nanoparticle Delivery of Alu RNA Adjuvants Enhances Vaccine Immunogenicity

Alexander J. Kwiatkowski, Jacob A. Schulman, Hayden M. Pagendarm, Lucinda E. Pastora, John T. Tossberg, Ruilin Zhang, Neil C. Chada, Mia E. Woodruff, Taylor L. Sheehy, Karan Arora, John Karijolich, Thomas M. Aune, John T. Wilson

ACS Applied Materials & Interfaces· Volume 17· Issue 36

Abstract

High Resolution Image Download MS PowerPoint Slide Vaccine adjuvants stimulate innate immunity to enhance and shape adaptive immune responses. However, approved adjuvants typically elicit weak CD8 + T cell responses to protein- and peptide-based vaccines, motivating an investigation into the discovery and testing of new adjuvants. Unedited forms of endogenous Alu RNAs are sensed by pattern recognition receptors (PRRs) to trigger sterile inflammation, and therefore we hypothesized that synthetic Alu RNA molecules could be harnessed as vaccine adjuvants. To enhance their intracellular delivery, Alu RNA was copackaged with a model antigen into polymer nanoparticles that promoted endosomal escape of Alu RNA to the cytosol. Using this nanovaccine formulation, we found that Alu RNA activated antigen-presenting cells in vitro and in vaccine-site draining lymph nodes in vivo. Furthermore, we demonstrated that vaccine formulations containing Alu RNA as an adjuvant elicited comparable CD8 + T cell responses to those containing the common but highly heterogeneous RNA adjuvant PolyIC, and that this response protected mice from tumor challenge. Based on this, we further evaluated the antitumor efficacy of nanovaccine formulations containing Alu RNA adjuvants in mice with established tumors, again observing comparable responses to formulations containing PolyIC. Finally, we found that nanovaccines adjuvanted with Alu RNA could improve responses to anti-PD-1 immune checkpoint blockade in tumor-bearing mice. Overall, this study demonstrates that unedited Alu RNA coformulated with antigen in polymer nanoparticles can be harnessed as an effective vaccine adjuvant for stimulating CD8 + T cell responses with antitumor function and may offer a sequence-defined alternative to PolyIC.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · interferon and immune responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemical and Biomolecular Engineering

Vanderbilt University

Department of Biomedical Engineering

Department of Medicine

Vanderbilt University Medical Center

Department of Pathology, Microbiology, and Immunology

Vanderbilt Institute for Infection, Immunology, and Inflammation

Vanderbilt Center for Immunobiology

Vanderbilt-Ingram Cancer Center

Vanderbilt Institute of Chemical Biology

Funding

National Science Foundation Graduate Research Fellowship Program · National Cancer Institute · National Institute of Diabetes and Digestive and Kidney Diseases · National Institute of Allergy and Infectious Diseases · National Institute of Biomedical Imaging and Bioengineering · Division of Chemical, Bioengineering, Environmental, and Transport Systems

References (58)

Show source-provided references
1. 10.1038/s41568-021-00346-010.1038/s41568-021-00346-0 ↗
2. 10.1172/JCI8000910.1172/JCI80009 ↗
3. 10.1016/j.biomaterials.2017.03.03410.1016/j.biomaterials.2017.03.034 ↗
4. 10.1016/j.ejps.2011.08.01610.1016/j.ejps.2011.08.016 ↗
5. 10.1021/acs.chemrev.5b0010910.1021/acs.chemrev.5b00109 ↗
6. 10.3390/cancers1324618910.3390/cancers13246189 ↗
7. 10.3389/fimmu.2014.0014910.3389/fimmu.2014.00149 ↗
8. 10.1084/jem.2004124010.1084/jem.20041240 ↗
9. 10.1016/S1074-7613(02)00480-610.1016/S1074-7613(02)00480-6 ↗
10. 10.1111/j.0105-2896.2004.00200.x10.1111/j.0105-2896.2004.00200.x ↗
11. 10.1016/j.immuni.2010.10.00210.1016/j.immuni.2010.10.002 ↗
12. 10.1172/JCI7991510.1172/JCI79915 ↗
13. 10.2174/138161201339724910.2174/1381612013397249 ↗
14. 10.3389/fcell.2021.63377610.3389/fcell.2021.633776 ↗
15. 10.1038/s41551-022-01000-210.1038/s41551-022-01000-2 ↗
16. 10.1038/s43018-022-00418-610.1038/s43018-022-00418-6 ↗
17. 10.3389/fimmu.2018.0071110.3389/fimmu.2018.00711 ↗
18. 10.1586/14760584.2015.96608510.1586/14760584.2015.966085 ↗
19. 10.1016/j.pharmthera.2014.09.01010.1016/j.pharmthera.2014.09.010 ↗
20. 10.1007/s00262-005-0114-610.1007/s00262-005-0114-6 ↗
21. 10.1038/s41577-020-0288-310.1038/s41577-020-0288-3 ↗
22. 10.1038/nrm.2015.410.1038/nrm.2015.4 ↗
23. 10.1186/s13045-022-01261-z10.1186/s13045-022-01261-z ↗
24. 10.1074/jbc.TM118.00416610.1074/jbc.TM118.004166 ↗
25. 10.4049/jimmunol.200038410.4049/jimmunol.2000384 ↗
26. 10.1186/s13046-023-02727-910.1186/s13046-023-02727-9 ↗
27. Sun Y. · Am. J. Cancer Res. · 2020 · 10 · 148
28. 10.1186/s13000-017-0600-010.1186/s13000-017-0600-0 ↗
29. 10.1016/j.copbio.2018.08.00610.1016/j.copbio.2018.08.006 ↗
30. 10.1038/s41392-019-0089-y10.1038/s41392-019-0089-y ↗
31. 10.1038/s41388-020-01515-510.1038/s41388-020-01515-5 ↗
32. 10.1038/s41586-018-0768-910.1038/s41586-018-0768-9 ↗
33. 10.1038/s43018-025-00907-410.1038/s43018-025-00907-4 ↗
34. 10.1073/pnas.85.13.477510.1073/pnas.85.13.4775 ↗
35. 10.1007/BF0251538310.1007/BF02515383 ↗
36. 10.1093/braincomms/fcac23810.1093/braincomms/fcac238 ↗
37. 10.3389/fimmu.2022.81802310.3389/fimmu.2022.818023 ↗
38. 10.3389/fimmu.2022.81802310.3389/fimmu.2022.818023 ↗
39. 10.1158/2767-9764.CRC-22-035410.1158/2767-9764.CRC-22-0354 ↗
40. 10.1208/s12248-009-9143-y10.1208/s12248-009-9143-y ↗
41. 10.1002/jps.2224310.1002/jps.22243 ↗
42. 10.1016/j.coche.2014.11.00310.1016/j.coche.2014.11.003 ↗
43. 10.1002/JLB.5BT0119-016R10.1002/JLB.5BT0119-016R ↗
44. 10.1016/j.addr.2020.06.01910.1016/j.addr.2020.06.019 ↗
45. 10.1021/acsnano.3c0447110.1021/acsnano.3c04471 ↗
46. 10.1021/acsnano.9b0032610.1021/acsnano.9b00326 ↗
47. 10.1038/nature1297810.1038/nature12978 ↗
48. 10.1038/nmat296010.1038/nmat2960 ↗
49. 10.1016/j.jconrel.2022.03.02010.1016/j.jconrel.2022.03.020 ↗
50. 10.1016/0041-008X(72)90098-110.1016/0041-008X(72)90098-1 ↗
51. 10.1016/j.bbi.2019.08.00610.1016/j.bbi.2019.08.006 ↗
52. 10.1016/j.cell.2022.06.03510.1016/j.cell.2022.06.035 ↗
53. 10.3389/fimmu.2021.62793210.3389/fimmu.2021.627932 ↗
54. 10.1016/j.biomaterials.2013.10.00310.1016/j.biomaterials.2013.10.003 ↗
55. 10.1038/s41388-020-1248-x10.1038/s41388-020-1248-x ↗
56. 10.1016/j.canlet.2022.21599510.1016/j.canlet.2022.215995 ↗
57. 10.1186/gb-2014-15-2-r2810.1186/gb-2014-15-2-r28 ↗
58. 10.1038/ng122310.1038/ng1223 ↗